EVLO (Evelo Biosciences) Other Current Payables: $0.00 Mil (As of Sep. 2023)


What is Evelo Biosciences Other Current Payables?

Evelo Biosciences EVLO -99.00% Other Current Payables is $0.00 Mil as of Sep. 2023.

Evelo Biosciences's Other Current Payables for the quarter that ended in Sep. 2023 was $0.00 Mil.


Evelo Biosciences Other Current Payables Related Terms


Evelo Biosciences Other Current Payables Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences Other Current Payables Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evelo Biosciences Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Evelo Biosciences (EVLO) has a Other Current Payables of $0.00 Mil as of Sep. 2023. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' Other Current Payables too high?
Evelo Biosciences' current Other Current Payables is $0.00 Mil.
How does Evelo Biosciences' Other Current Payables compare to IMNN and EDSA?
Evelo Biosciences' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current Other Current Payables of $0.00 Mil. The current Other Current Payables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current Other Current Payables is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.